352 related articles for article (PubMed ID: 21321566)
21. MicroRNAs in the prognosis and therapy of colorectal cancer: From bench to bedside.
To KK; Tong CW; Wu M; Cho WC
World J Gastroenterol; 2018 Jul; 24(27):2949-2973. PubMed ID: 30038463
[TBL] [Abstract][Full Text] [Related]
22. Identification of colorectal cancer patients with tumors carrying the TP53 mutation on the codon 72 proline allele that benefited most from 5-fluorouracil (5-FU) based postoperative chemotherapy.
Godai TI; Suda T; Sugano N; Tsuchida K; Shiozawa M; Sekiguchi H; Sekiyama A; Yoshihara M; Matsukuma S; Sakuma Y; Tsuchiya E; Kameda Y; Akaike M; Miyagi Y
BMC Cancer; 2009 Dec; 9():420. PubMed ID: 19954513
[TBL] [Abstract][Full Text] [Related]
23. Construction and optimization of gene expression signatures for prediction of survival in two-arm clinical trials.
Theilhaber J; Chiron M; Dreymann J; Bergstrom D; Pollard J
BMC Bioinformatics; 2020 Jul; 21(1):333. PubMed ID: 32711453
[TBL] [Abstract][Full Text] [Related]
24. A network-based predictive gene expression signature for recurrence risks in stage II colorectal cancer.
Yang WJ; Wang HB; Wang WD; Bai PY; Lu HX; Sun CH; Liu ZS; Guan DK; Yang GW; Zhang GL
Cancer Med; 2020 Jan; 9(1):179-193. PubMed ID: 31724326
[TBL] [Abstract][Full Text] [Related]
25. Involvement of Non-coding RNAs in Chemo- and Radioresistance of Colorectal Cancer.
Fanale D; Castiglia M; Bazan V; Russo A
Adv Exp Med Biol; 2016; 937():207-28. PubMed ID: 27573902
[TBL] [Abstract][Full Text] [Related]
26. Current trends in clinical genetics of colorectal cancer.
Markovic S; Dimitrijevic I; Zogovic B; Markovic V; Barisic G; Krivokapic Z
J BUON; 2016; 21(5):1042-1049. PubMed ID: 27837603
[TBL] [Abstract][Full Text] [Related]
27. A set of defined oncogenic mutation alleles seems to better predict the response to cetuximab in CRC patient-derived xenograft than KRAS 12/13 mutations.
Chen D; Huang X; Cai J; Guo S; Qian W; Wery JP; Li QX
Oncotarget; 2015 Dec; 6(38):40815-21. PubMed ID: 26512781
[TBL] [Abstract][Full Text] [Related]
28. Exosomes as potential sources of biomarkers in colorectal cancer.
Xiao Y; Zhong J; Zhong B; Huang J; Jiang L; Jiang Y; Yuan J; Sun J; Dai L; Yang C; Li Z; Wang J; Zhong T
Cancer Lett; 2020 Apr; 476():13-22. PubMed ID: 32044357
[TBL] [Abstract][Full Text] [Related]
29. Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?
Rizzo S; Bronte G; Fanale D; Corsini L; Silvestris N; Santini D; Gulotta G; Bazan V; Gebbia N; Fulfaro F; Russo A
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S56-61. PubMed ID: 21129611
[TBL] [Abstract][Full Text] [Related]
30. Biomarker-based prediction of response to therapy for colorectal cancer: current perspective.
Ross JS; Torres-Mora J; Wagle N; Jennings TA; Jones DM
Am J Clin Pathol; 2010 Sep; 134(3):478-90. PubMed ID: 20716806
[TBL] [Abstract][Full Text] [Related]
31. The evolution of our molecular understanding of colorectal cancer: what we are doing now, what the future holds, and how tumor profiling is just the beginning.
Dienstmann R; Salazar R; Tabernero J
Am Soc Clin Oncol Educ Book; 2014; ():91-9. PubMed ID: 24857065
[TBL] [Abstract][Full Text] [Related]
32. Prognostic DNA methylation markers for sporadic colorectal cancer: a systematic review.
Draht MXG; Goudkade D; Koch A; Grabsch HI; Weijenberg MP; van Engeland M; Melotte V; Smits KM
Clin Epigenetics; 2018; 10():35. PubMed ID: 29564023
[TBL] [Abstract][Full Text] [Related]
33. Drug resistance, predictive markers and pharmacogenomics in colorectal cancer.
Longley DB; Allen WL; Johnston PG
Biochim Biophys Acta; 2006 Dec; 1766(2):184-96. PubMed ID: 16973289
[TBL] [Abstract][Full Text] [Related]
34. Development and interpretation of a pathomics-based model for the prediction of microsatellite instability in Colorectal Cancer.
Cao R; Yang F; Ma SC; Liu L; Zhao Y; Li Y; Wu DH; Wang T; Lu WJ; Cai WJ; Zhu HB; Guo XJ; Lu YW; Kuang JJ; Huan WJ; Tang WM; Huang K; Huang J; Yao J; Dong ZY
Theranostics; 2020; 10(24):11080-11091. PubMed ID: 33042271
[TBL] [Abstract][Full Text] [Related]
35. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab.
Peeters M; Douillard JY; Van Cutsem E; Siena S; Zhang K; Williams R; Wiezorek J
J Clin Oncol; 2013 Feb; 31(6):759-65. PubMed ID: 23182985
[TBL] [Abstract][Full Text] [Related]
36. Personalized treatment for patients with colorectal cancer: role of biomarkers.
Duffy MJ
Biomark Med; 2015; 9(4):337-47. PubMed ID: 25808438
[TBL] [Abstract][Full Text] [Related]
37. Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview.
Lin PS; Semrad TJ
Methods Mol Biol; 2018; 1765():281-297. PubMed ID: 29589315
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer.
Saridaki Z; Georgoulias V; Souglakos J
World J Gastroenterol; 2010 Mar; 16(10):1177-87. PubMed ID: 20222160
[TBL] [Abstract][Full Text] [Related]
39. Rationale and design of the BRAVERY study (EPOC1701): a multicentre phase II study of eribulin in patients with
Masuishi T; Taniguchi H; Kotani D; Bando H; Komatsu Y; Shinozaki E; Nakajima TE; Satoh T; Nishina T; Esaki T; Wakabayashi M; Nomura S; Takahashi K; Ono H; Hirano N; Fujishiro N; Fuse N; Sato A; Ohtsu A; Yoshino T
ESMO Open; 2019; 4(6):e000590. PubMed ID: 31798981
[TBL] [Abstract][Full Text] [Related]
40. Survival marker genes of colorectal cancer derived from consistent transcriptomic profiling.
Martinez-Romero J; Bueno-Fortes S; MartÃn-Merino M; Ramirez de Molina A; De Las Rivas J
BMC Genomics; 2018 Dec; 19(Suppl 8):857. PubMed ID: 30537927
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]